Jascayd

FDA批准JASCAYD：近10年首款IPF新药，中国同步布局

美国FDA批准JASCAYD®（nerandomilast）用于成人特发性肺纤维化（IPF）治疗，这是十年来FDA批准的首个新IPF疗法。中国的IPF及PPF上市申请也已获NMPA受理。

Jascayd

FDA Approves JASCAYD® (Nerandomilast) for Idiopathic Pulmonary Fibrosis — First New Therapy in Over a Decade

Boehringer Ingelheim’s JASCAYD® (nerandomilast) gains FDA approval for IPF, offering an oral PDE4B inhibitor with favorable tolerability and the first new treatment option in 10+ years.